Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paclitaxel liposomal - Syncore Biotechnology

Drug Profile

Paclitaxel liposomal - Syncore Biotechnology

Alternative Names: EndoTAG-1; MBT-0206; SB 05

Latest Information Update: 14 Sep 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California at San Francisco
  • Developer Jules Bordet Institute; MediGene AG; SynCore Biotechnology
  • Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes
  • Mechanism of Action Angiogenesis inhibitors; Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No
  • Available For Licensing Yes - Pancreatic cancer

Highest Development Phases

  • Phase III Breast cancer; Pancreatic cancer
  • No development reported Colorectal cancer; Gastrointestinal cancer; Liver cancer; Prostate cancer

Most Recent Events

  • 12 Sep 2018 Ministry of Healthcare of the Russian Federation approves liposomal paclitaxel for phase III trials for Pancreatic cancer in Russia
  • 12 Sep 2018 SynCore Biotechnology receives approval to conduct phase III trials of paclitaxel liposomal for Pancreatic Cancer in USA, France and South Korea
  • 22 Aug 2018 OGYEI approves liposomal paclitaxel for phase III trials for Pancreatic cancer in Hungary
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top